VLA-1601
- Generic Name
- VLA-1601
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
Phase 1
Active, not recruiting
- Conditions
- ZikaZika Virus Infection
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT06334393
- Locations
- 🇺🇸
Flourish Research, Chicago, Illinois, United States
🇺🇸Velocity Clinical Research, Omaha, Nebraska, United States
🇺🇸Flourish Research, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath